Let’s get real on synthetic biology: The seeing watchmaker by Marris, C. & Rose, N.
Marris, C. & Rose, N. (2012). Let’s get real on synthetic biology: The seeing watchmaker. New 
Scientist, 214(2868), pp. 28-29. 
City Research Online
Original citation: Marris, C. & Rose, N. (2012). Let’s get real on synthetic biology: The seeing 
watchmaker. New Scientist, 214(2868), pp. 28-29. 
Permanent City Research Online URL: http://openaccess.city.ac.uk/13482/
 
Copyright & reuse
City University London has developed City Research Online so that its users may access the 
research outputs of City University London's staff. Copyright © and Moral Rights for this paper are 
retained by the individual author(s) and/ or other copyright holders.  All material in City Research 
Online is checked for eligibility for copyright before being made available in the live archive. URLs 
from City Research Online may be freely distributed and linked to from other web pages. 
Versions of research
The version in City Research Online may differ from the final published version. Users are advised 
to check the Permanent City Research Online URL above for the status of the paper.
Enquiries
If you have any enquiries about any aspect of City Research Online, or if you wish to make contact 
with the author(s) of this paper, please email the team at publications@city.ac.uk.
28 | NewScientist | 9 June 2012
EXCITING but terrifying. Powerful 
but scary. This is what some say 
about the emerging field of 
synthetic biology. Not surprising, 
perhaps, for an initiative that 
aims to “create life from scratch”, 
to “make life better” and to “make 
biology easier to engineer”.
The goals of synthetic biology 
are certainly ambitious: to 
produce a toolbox of standard 
biological parts with well-
characterised functions that can 
be put together in combinations 
that may not exist in nature in 
order to perform human-
designed functions outside the 
laboratory. Some hope to make 
the parts and the knowledge of 
how to assemble them accessible 
to all. The overall aim is to make 
the engineering of biology a 
routine process that can be put to 
use in many industries, with no 
need for highly specialised skills.
Most ethical, policy and media 
discussions about synthetic 
biology start from the assumption 
that these aims have already been 
achieved: that biology has become 
easy to engineer for whatever 
ends we choose, that the toolbox 
is available to any student or 
potential terrorist, that dangerous 
organisms and powerful 
bioweapons are easy to make, and 
that no effective regulation is 
possible. The ability of synthetic 
biologists to overcome serious 
scientific and technological 
challenges is taken for granted, 
and the economic, legal, social 
and political conditions for the 
uptake of these technologies 
are ignored.
Commentators instead focus 
on potential reckless use or 
misuse, overestimate the 
pathogenic possibilities, and 
worry about deep questions such 
as: “Do we have the right to play 
God?”. These worries are the flip 
side of grand claims about 
synthetic biology’s imminent 
ability to solve challenges in 
health, environment and energy. 
Utopias and dystopias seem to be 
the only scenarios possible.
This way of framing discussions 
is unhelpful. It is an example of 
“speculative ethics” that distracts 
us from less exciting but more 
pressing questions. What are 
synthetic biologists actually 
doing? How easy, or difficult, is it 
proving? What applications are 
they realistically going to develop 
in the short to medium term? 
What is their intended purpose, 
and to what extent could these 
contribute to the public good?
How, then, to proceed? 
Synthetic biologists have 
been impressively open to 
collaborations with the social 
sciences, law, arts and humanities, 
and open to debates with critical 
groups. In the UK, for example, 
social scientists have been  
participating in synthetic biology 
research programmes from 
the outset.
We are engaged in such 
partnerships and work closely 
with synthetic biologists so 
that together we can better 
understand the promises and 
challenges. We aim to help them 
reflect on why they are doing what 
they are doing, and to encourage 
them to open up such reflections 
to people outside their labs. In so 
doing, we try to avoid the pitfalls 
of speculative ethics and – 
perhaps idealistically – influence 
the kind of synthetic biology that 
is developed.
Science is creative, exciting  
and future-oriented and most 
synthetic biologists, like most 
people, do want to “make life 
better”. But this means different 
things to different people, and 
even among synthetic biologists 
there are different views about 
what research is most valuable 
and which directions should 
be pursued.
As “embedded” social 
scientists, we routinely witness 
fascinating, nuanced discussions 
among synthetic biologists that 
acknowledge the complexities 
and uncertainties involved in 
their research. Sadly, these often 
disappear when synthetic 
biologists present their work 
in official public dialogues – or 
to journalists.
It is often left up to the most 
vocal critics of new technologies 
to articulate the complexities in 
public, and this is also the case for 
synthetic biology. When a number 
of NGOs led by opponents of 
genetic technology issued a 
declaration entitled The Principles 
for the Oversight of Synthetic 
Biology this year, most of the 
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discussion focused on their call 
for a limited moratorium. Yet 
much of the document in fact 
focused on the debatable 
desirability of the goals of 
synthetic biology, and on the 
need to acknowledge the 
complexities and uncertainties 
involved in designing novel living 
organisms – issues which concern 
many of those working in 
synthetic biology and which can 
and should be the subject of 
open debate.
Discussions about the inherent 
complexities and uncertainties, 
and about desirable futures, 
should be opened up to a whole 
range of social groups, not least 
those who have anxieties and 
criticisms. This might take us 
beyond the limits of most 
previous public-engagement 
exercises, and it could help ensure 
a more democratic process in 
which different visions of what 
is desirable are debated before 
particular ones become 
entrenched and hard to modify.
Such conversations should also 
help move the discussion beyond 
speculation about utopias and 
dystopias, by recognising that the 
prospects for synthetic biology 
are likely to be both less 
sensational and less forbidding 
than is generally acknowledged. 
A meeting run by the science 
and engineering academies of the 
UK, US and China that will take 
place in Washington DC next week 
aims to assess the prospects for 
synthetic biology, and the 
concerns about its potential, 
by bringing together natural 
scientists, social scientists, artists, 
regulators, science funders and 
critical NGOs. Let’s hope that this 
is a key moment in developing the 
kind of dialogue that is essential if 
the potential of synthetic biology 
is to be realised.  n
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How do the drug laws in most countries 
affect scientific research?
One of the things I find very disturbing about the 
current approach to drugs, which is simply 
prohibition without necessarily any full 
understanding of harms, is that we lose sight of 
the fact that these drugs may well give us insights 
into areas of science that need to be explored and 
may give us new opportunities for treatment.
In what way?
Almost all the drugs of interest in terms of 
understanding brain phenomena such as 
consciousness, perception, mood and psychosis 
are illegal. And so there is almost no work done in 
this field. 
How bad is the impact?
The effects these laws have had on research is 
greater than those caused by the US government 
stopping stem cell research. No one has done an 
imaging neuroscience study of smoking cannabis. 
I can show you 150 papers telling you how the 
brain reacts to an angry face, but I can’t show you 
a single paper that tells you what cannabis does.
Any examples of missed opportunities?
There were six trials of LSD as a treatment for 
alcoholism, the last one in 1965. The evidence is 
it’s as good as anything we’ve got, maybe better. 
But no one is using it for this. I wonder how many 
other opportunities have been lost in the past 40 
years with important drugs like MDMA (ecstasy) 
and its empathetic qualities or cannabis for all its 
possible uses and insights into conditions like 
schizophrenia. All those opportunities have been 
wasted because it is virtually impossible to work 
with a drug when it is illegal. 
How do you see change coming about?
The scientific bodies in the UK are the ones that 
should really be challenging the government. I will 
try to get the Royal Society and the Academy of 
Medical Sciences to support this campaign for a 
more rational approach to the regulation of drugs 
for research. 
One minute with...
David Nutt
You were sacked as a UK government adviser 
for comparing the risks of horse riding with 
taking MDMA. Do you still take this line?
It is still a very important discussion. It raises the 
question of what the appropriate comparisons are. 
Where do you draw the line on harm? Should it be 
drawn equally across all sorts of endeavours and 
activities that humans engage in? 
Should recreational-drug laws be relaxed?
If you are using a drug less dangerous than 
alcohol, that is a rational choice. If you are using 
drugs that are more harmful than alcohol, 
essentially heroin or other forms of opiates and 
crystal meth and cocaine, then that’s different.
As head of the UK Independent Scientific 
Committee on Drugs you’ve written a book, 
Drugs: Without the hot air. Who is it for?
Parents and those with no scientific background 
can read it, children can read it and hopefully the 
media and politicians will read it. I hope we can 
start having more of a discussion about drugs.
Interview by Jon White
Outlawing drugs like ecstasy is hampering the hunt for new 
medical treatments, says the ex-government adviser 
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